Search
Now showing items 1-6 of 6
Immunomodulatory Effects Associated with Cladribine Treatment
(2021-12)
Cladribine is a synthetic deoxyadenosine analogue with demonstrated efficacy in patients with relapsing-remitting multiple sclerosis (MS). The main mechanism of action described for cladribine is the induction of a cytotoxic ...
Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results
(2017-02-07)
Antibodies against biopharmaceuticals (anti-drug antibodies, ADA) have been a well-integrated part of the clinical care of multiple sclerosis (MS) in several European countries. ADA data generated in Europe during the more ...
CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS
(2021-03)
Objective To identify biomarkers associated with progressive phases of MS and with neuroprotective potential.
Methods Combined analysis of the transcriptional and proteomic profiles obtained in CNS tissue during chronic ...
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
(2021-07)
Objectives The study aimed to assess the potential for serum neurofilament light chain (NFL) levels to predict the risk of progressive multifocal leukoencephalopathy (PML) in natalizumab (NTZ)-treated patients with multiple ...
Association of magnetic resonance imaging phenotypes and serum biomarker levels with treatment response and long-term disease outcomes in multiple sclerosis patients
(2024-01)
Background and purpose
The aim was to evaluate whether magnetic resonance imaging (MRI) phenotypes defined by inflammation and neurodegeneration markers correlate with serum levels of neurofilament light chain (NfL) and ...